- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01565109
NESC: Neoadjuvant Treatment Of Gastric Adenocarcinoma
Phase II Multicenter Study in the Preoperative Treatment of Gastric Adenocarcinoma Consisting of Chemotherapy Using Docetaxel-cisplatin-5FU + Lenograstim Followed by Chemoradiation Based 5FU and Oxaliplatin
It is estimated to 7300 the number of new cases of gastric cancer each year in France.
According to a randomized trial comparing 3 cycles of ECF (epirubicin, cisplatin, 5FU) administered before surgery and 3 cycles after surgery with surgery alone in adenocarcinoma of the stomach and lower esophagus, clinical and experimental data are the neoadjuvant chemotherapy is a new standard treatment for operable gastric cancer. This treatment with a median survival of more than 3 years to obtain a hazard ratio of 0.75 in favor of chemotherapy arm (p = 0.009). The 5-year survival being 36% for patients treated with chemotherapy versus 23% for surgery alone. Progression-free survival was also significantly prolonged with a hazard ratio of 0.66.
The proposed clinical study by Ajani et al shows that the combination of Docetaxel with the schema Cisplatin - 5FU provides greater clinical benefit and induces to consider the triple combination as a reference treatment in metastatic gastric cancer in patients under 65 years.
Preoperative radiochemotherapy is expected to increase the rate of curative resections, reduce gastrointestinal and hematologic toxicity.
Two studies evaluating the feasibility of preoperative RTCT in operable gastric adenocarcinoma with continuous 5GU (+ or - paclitaxel) and 45 Gy are available and the combination 5FU oxaliplatin has been assessed in the esophagus and rectum tumors.
The NESC study, Phase II, proposes the following schema: 2 cycles of chemotherapy with Docetaxel - Cisplatin - 5FU then preoperative chemoradiation with oxaliplatin - continuous 5FU and radiotherapy in locally advanced gastric adenocarcinoma stage III and IV non-metastatic administered before surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Avignon, France, 84000
- Recruiting
- Institut Sainte Catherine
-
Contact:
- LAURENT MINEUR, DOCTOR
- Phone Number: 04.90.27.62.68
- Email: l.mineur@isc84.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients, Age: 18 to 65
- ECOG performance status of ≤ 1
- Histological documentation of the gastric adenocarcinoma. An extension will be admitted to the omentum
- Adenocarcinoma of the stomach according to staging classification TNM Scannographic: T2bN0, T2bN1, T3NO T3N +, T4N0, and T4N + M0 (cardia, Siewert II, III, fundus, body, antrum) performed by ultrasonography and CT Scan. Optional : laparoscopy
- A positive peritoneal cytology is not a disqualifying factor if there is no macroscopic carcinomatosis
- Absence of previous abdominal irradiation above the 5th sacral vertebra (in the liver, pancreas, spleen, or mediastinal lodge)
- Loss of weight less than 15% over the base weight before diagnosis
- No psychological, familial, sociological or geographical condition that may affect compliance and adherence to treatment, patient monitoring or understanding of the study.
- Signed informed consent obtained before any study specific procedures.
- Food Consumption> 1000 calories / day whatever the mode of administration (enteral or parenteral)
Laboratory test conducted within one week of starting to study treatment:
- Absolute neutrophil count > 1500/mm3
- Platelet count > 100 000/mm3
- Total bilirubin <2 mg/dL
- Serum creatinine <13 mg/dL or creatinine clearance > 40 ml/min
- Hemoglobin (Hgb) ≥ 10 g/dL (Hemoglobin transfusion if necessary)
- ALT / AST <1.5 x ULN
- PTT ≥ 60 %
- Life expectancy of at least 3 months
Exclusion Criteria:
- Peripheral sensory neuropathy ≥ grade 1 (according to CTCAE version 3.0).
- Myocardial infarction, stroke or pulmonary embolism, unstable angina less than 6 months before start of study drug.
- Uncontrolled infection
- Pregnant or breast-feeding patients. Women of childbearing potential must have a pregnancy test performed.
- Prior treatment for gastric adenocarcinoma
- Lower limbs arteritis (≥ stage II according the Leriche and Fontain classification)
- Patient participating in another clinical trial or already receiving other anti-cancer treatment
- Concomitant treatment with a phenytoin
- Known previous / current malignancy within the last 5 years except for non-melanoma skin, non-metastatic prostate carcinoma and cervival carcinoma in situ or superficial bladder carcinoma.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm study
Docetaxel - Cisplatine - 5FU 2 cycles of Docetaxel - Cisplatine - 5 FU Radiation: Radiation of 45 Grays on 5 weeks Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks |
2 cycles of Docetaxel - Cisplatine - 5 FU
Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Histological response rate on surgical specimen after chemotherapy and chemoradiotherapy preoperative
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NESC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingMetastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
University of ChicagoNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer | Stage IIB Gastric Cancer | Stage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal AdenocarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Gastric Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Diffuse Gastric Adenocarcinoma | Gastric Intestinal Type Adenocarcinoma | Gastric Mixed AdenocarcinomaUnited States, Canada
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingGastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
Ukrainian Society of Clinical OncologyRecruitingStomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastrointestinal Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | GastroEsophageal Cancer | Stomach Neoplasm | Gastric Neoplasm | Advanced Gastric Carcinoma | Advanced Gastroesophageal Junction AdenocarcinomaUkraine
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States, Puerto Rico
-
M.D. Anderson Cancer CenterRecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
Clinical Trials on Docetaxel - Cisplatine - 5FU
-
University Hospital, RouenInstitut Curie; APHPRecruitingBladder Cancer | Chemotherapy EffectFrance
-
University Hospital, RouenInstitut CurieActive, not recruitingBladder Cancer | Genomic InstabilityFrance
-
Rabin Medical CenterDavidoff Cancer CenterUnknown
-
Dr Jean Yannis PERENTESRecruitingCarcinoma, Non-Small-Cell Lung | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Mesothelioma, Malignant | Carcinoma Breast Stage IVSwitzerland
-
Hospital Alemão Oswaldo CruzRecruitingRectal Cancer | ConsolidationBrazil, Argentina, Uruguay
-
Intergroupe Francophone de Cancerologie ThoraciqueTerminatedCarcinoma, Non-Small-Cell LungFrance
-
Swiss Group for Clinical Cancer ResearchCompletedGastric CancerSwitzerland, Italy
-
HealthCare Global Enterprise Ltd.UnknownSquamous Cell Carcinoma | Tongue Neoplasms | Anterior Tongue Squamous Cell CarcinomaIndia
-
Groupe Oncologie Radiotherapie Tete et CouActive, not recruitingHead and Neck Squamous Cell CarcinomaFrance
-
Mast Therapeutics, Inc.University of California, San DiegoCompletedRectal Cancer | Colon CancerUnited States, Former Serbia and Montenegro